Fortress Biotech, Inc.

NASDAQ:FBIO

Biotechnology

Healthcare
$1.89 -1.79%

-$0.06 today

Market cap
$63.03M
Beta
1.23
P/E (TTM)
0.7
EPS (TTM)
$4.05
52W Low $1.70High $4.53

Volume 0.41M

Average 0.43M

FBIO Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

Fortress Biotech, Inc.NASDAQ: FBIO

Accounts Payables · Q1 FY2026 · quarter ended Mar 2026

Accounts payables growth accelerates

Q1 FY2026 accounts payables of $45.94M rose 8252.2% year over year, ahead of the +505.9% change in trailing-twelve-month accounts payables. Sequentially, it rose 1615.3% from the prior quarter.

Context

  • Accounts payables amounted to 12.6% of revenue in FY2025, up 1.5 pp from a year earlier.
  • Accounts payables increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +8252.2% holds above the trailing-twelve-month pace of +505.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$45.94M+1615.3% QoQ
Last fiscal yearDec 2025
-$7.97M+24.7% YoY
LTMMar 2026
$37.42M+505.9% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+8252.2%——
1 year+24.7%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
(7.97M) USD
Year-over-year change
-24.7%

Accounts Payables vs competitors

How FBIO compares with its peers on the latest reported figures

  • FBIO's LTM Mar 2026 accounts payables of $37.42M is the largest of the 10 companies compared; the peer median is $0.
  • Its year-over-year change of +505.9% is the 2nd highest of 9, against a peer median of -62.2%.
  • Accounts payables amounts to 56.6% of revenue for FBIO, versus a peer median of 15.3%.
FBIO Competitors Peer median
Accounts Payables for FBIO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
FBIOFortress Biotech, Inc.LTM Mar 2026$37.42M +505.9%—56.6%
VXRTVaxart, Inc.LTM Mar 2026$7.56M -40.6%+244.8%3.0%
IMUXImmunic, Inc.LTM Mar 2026$4.41M +702.6%+15.7%—
TCRXTScan Therapeutics, Inc.LTM Mar 2026$2.52M -185.2%—27.6%
RLMDRelmada Therapeutics, Inc.LTM Mar 2026$2.07M +152.7%——
PMVPPMV Pharmaceuticals, Inc.LTM Mar 2026$1.96M -171.6%+106.5%—
GANXGain Therapeutics, Inc.LTM Mar 2026$1.05M -253.3%——
NTRBNutriband Inc.LTM Apr 2026$807.73K +401.9%—44.8%
XBITXBiotech Inc.LTM Mar 2026$241K -83.9%——
ADAGAdagene Inc.LTM Jun 2024$0 ——0.0%
Peer median (excluding FBIO) $0-62.2%+106.5%15.3%

Competitors are the stored peer set for FBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(164.83M)(213.91M)(154.15M)(120.86M)(32.92M)
Depreciation & Amortization6.79M9.35M6M4.46M4.66M
Deferred Income Tax00000
Stock-Based Compensation19.49M22.99M17.03M32.62M28.74M
Change in Working Capital36.37M(715K)(12.52M)(8.13M)(25.1M)
Accounts Receivables834K(4.84M)12.52M4.47M(19.33M)
Inventory(8.46M)1.74M3.95M(4.23M)4.81M
Accounts Payables43.31M8.35M(24.38M)(6.39M)(7.97M)
Other Working Capital690K(5.97M)(4.61M)(1.98M)(2.6M)
Other Non-Cash Items(14.36M)2.89M15.42M11.71M(41.17M)
Operating Cash Flow(116.54M)(179.4M)(128.23M)(80.19M)(65.78M)
Capital Expenditures(16.35M)(3.06M)(8.1M)(15M)0
Acquisitions (Net)56.86M(20M)008.96M
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities(11.78M)(213K)(2.04M)01.17M
Investing Cash Flow40.51M(22.93M)(2.1M)(15M)10.12M
Debt Repayment(9.64M)49.25M(38.79M)(7.33M)(5.64M)
Common Stock Issued155.26M40.26M80.38M82.84M84.63M
Common Stock Repurchased0(1.11M)00(265K)
Dividends Paid(8.78M)(8.78M)(8.77M)(4.71M)(664K)
Other Financing Activities(4.8M)(6.74M)(529K)(163K)(360K)
Financing Cash Flow148.99M75.32M32.74M70.64M77.44M
Effect of Forex Changes00000
Net Change in Cash72.97M(127.01M)(97.59M)(24.55M)21.79M
Free Cash Flow(132.89M)(182.46M)(136.32M)(95.19M)(65.78M)

Fortress Biotech, Inc.

NASDAQ:FBIO

Intrinsic Alpha fair value

Locked

Current Price

$1.89

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.